Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: angra manyu who wrote (581)	5/4/1998 8:20:00 PM
From: Brian Malloy	Read Replies (1) \| Respond to of 2135

Check this post: Message 4320917 + TNP-470 made by TAP Pharmaceuticals of Japan

To: angra manyu who wrote (581)	5/4/1998 8:38:00 PM
From: Bottom_Dweller	Read Replies (3) \| Respond to of 2135

ENMD - The FACTS ENMD and their scientists have done great work, but there are a number of reasons this company is not currently a sound investment at these levels: 1) The recent news articles have been very very good for the overall cancer community, because now there is increased interest in the investment community of searching for a cure for cancer, and as such it is possible more investment in cancer research may be made. The actual technical merit, however, could be compared to needing all the pieces to a puzzle, whereas we previously may have had 3% of the pieces to the "cure for cancer puzzle" we now have 5%. ENMD's work is very very significant, however, we still have a long journey to go, and more investment and ideas are needed. The CEO of ENMD admitted this publicly on CNBC today. 2) They are at least 12-18 months from even testing the theory in humans. Many compounds that work in mice, simply don't in humans. This was also admitted publicly by the company. 3) Their are a lot of competitors developing other significant works in the same strain of thinking. To name a few: SUGN, IMCL, BBIOY, BLSI, MAGN. Any one of these companies or others may actually be creating more pieces to the "cure for cancer puzzle". Some of the pieces they are working on could be more significant than ENMDs. 4) The company is losing a lot of money every quarter. The news could however trigger more investor interest. If there are no new investors, it is possible that in 6-9 months at their current loss rates they will go bankrupt, pure and simple. 5) The following comment is not meant to detract from the quality of work being done at ENMD, it is only my speculation after reading through their balance sheets. The news is actually quite old, read through their past press releases. It almost seems as though their money-losing problem could have triggered their desire to draw more publicity to their stock and company. If the company was making a lot of money, and then publicized their work, I would be less suspect, but a company that is losing money, is, well, losing money. 6) Many brokerages have moved this stock to non-margin status. The official reason for doing this from a DATEK official "You could lose your house on this stock." Brokers don't make sound investment stock opportunities non-margin. Kyle.. (to qualify myself, I hold a short position in the stock).